Victrex (VCT) H2 2025 earnings summary

Executive summary

• Achieved 12% sales volume growth in FY 2025, but revenue increased only 1% due to adverse currency and sales mix impacts.

• Underlying profit before tax declined 21% to GBP 46.4 million, mainly due to FX, China start-up costs, and sales mix; reported PBT rose 44% due to lower exceptionals.

• Profit improvement plan underway, targeting at least GBP 10 million in savings, leveraging digital and infrastructure investments, with full-year benefits expected in FY 2027.

• Cash conversion remained robust at 121%, aided by inventory reduction and lower CapEx.

• Updated capital allocation policy maintains dividends and targets net debt/EBITDA in the 0.5x–1.0x range.

Financial highlights

• Revenue rose 1% to GBP 292.7 million (+3% at constant currency), with gross profit down 1% to GBP 132.6 million.

• Gross margin declined 90 bps to 45.3% (47.7% excluding China plant impact).

• Underlying EPS fell 15% to GBP 0.439; effective tax rate increased to 23.9%.

• Free cash flow was GBP 49.3 million, with underlying operating cash conversion at 121%.

• Net debt increased to GBP 24.8 million, with net debt/EBITDA at 0.34x.

Outlook and guidance

• FY 2026 targets low to mid-single digit volume growth, stable ASP, and gross margin in the 45.5%–46.5% range.

• Medical spine remains weak; non-spine and sustainable solutions expected to drive growth.

• Profit improvement plan to deliver most benefits in FY 2027, with early gains in H2 2026 and exceptional costs of ~GBP 10 million.

• CapEx to remain disciplined at or below 8–10% of revenues, with further working capital opportunities.

• Guidance anticipates second-half weighted progress due to seasonality and currency headwinds in H1.